Alzheimer’s disease affects more than 35 million people, a number that is expected to increase in the coming years. Currently, Alzheimer’s diagnoses rely on clinical neuropathologic assessment of amyloid-beta peptide aggregates (plaques) and neurofibrillary tangles. But now researchers reveal that an enzyme already implicated in a host of neural disorders could someday serve as a biomarker.